ClinicalTrials.gg
Status unknownNCT04699643Updated Jan 7, 2021

FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of EVER4010001 in Advanced Solid Tumors, sponsored by EverNov Medicines (Zhuhai Hengqin) Co., Ltd. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-07.

Sponsored by EverNov Medicines (Zhuhai Hengqin) Co., Ltd · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jul 2020, registered Dec 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of EVER4010001 in combination with Pembrolizumab in Patients with Advanced Solid Tumors. And in phase II to assess the anti-tumor efficacy of EVER4010001 in combination with Pembrolizumab in treating selected indications using appropriate biomarkers.

Read the detailed description

This is a phase I/II, single arm, multicenter study of EVER4010001 combination with Pembrolizumab in advanced solid tumor patients. The primary endpoint of phase I will be Dose-limiting toxicities (DLTs) observed in combined administration of EVER4010001 and Pembrolizumab. And the primary endpoint of phase II will be the ORR per RECIST v1.1 in all treated patients.

Patients will be treated until progression requiring discontinuation of further treatment, unacceptable toxicity, study withdrawal, or death, whichever comes first. Tumor response and progression will be assessed using RECIST v1.1 and assessment by investigator at the trail center will be sufficient for decisions on continuation of treatment. All patients will visit the investigator at regular intervals for assessment of safety parameters and AEs.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

This is the only study on the registry with EverNov Medicines (Zhuhai Hengqin) Co., Ltd as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written must be obtained prior to any procedures that are related to this study.
  2. Patients (male or female) ≥ 18 years of age
  3. (ECOG) performance status≤1
  4. Presence of at least one according to the (RECIST) v1.1.
  5. Phase I study part: or cytologically confirmed or locally advanced solid tumors, for which no standard therapy exits or the standard therapy has failed.

Phase II study part: 1. Histologically or cytologically confirmed metastatic or locally advanced solid tumors of the selected indications. 2. Positive FGF19 in IHC test results of tumor tissues in pre-screening.

Exclusion criteria

Exclusion criteria:

  1. Prior therapies within the following time frames prior to the first dose of study treatment:

    • Last dose of conventional cytotoxic chemotherapy: ≤4 weeks ((≤ 6 weeks for nitrosoureas and mitomycin-C);
    • Drugs with anti-tumor activity (e.g., antibodies): ≤4 weeks
    • Non-cytotoxic small molecule therapeutics (e.g., sorafenib): ≤5 half-lives or ≤2 weeks (whichever is longer)
    • Previous wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) ≤ 4 weeks and limited field radiation for palliation ≤ 2 weeks (including particle implantation such as I125);
    • Participation in a prior study: ≤ 4 weeks;
    • Drugs with immunomodulatory activity (such as thymosin, interferon, interleukin, etc.) ≤ 6 weeks.
  2. Major surgery within 4 weeks of receiving the first dose of study treatment (mediastinoscopy, insertion of a central venous access device and insertion of a feeding tube are not considered major surgery).
  3. Subject having out of range laboratory values including hematology, chemistry and coagulation indicators. See Section 5.3 for specific indicators.
  4. Use of hematopoietic colony-stimulating growth factors (e.g. G-CSF, GM-CSF, M CSF), blood transfusion products (e.g., whole blood, plasma, apheresis , etc.), thrombopoietin mimetics or erythroid stimulating agents ≤ 2 weeks prior to start of study treatment. If erythroid stimulating agents were initiated more than 2 weeks prior to the first dose of study treatment and the patient is on a stable dose, they can be maintained.
  5. Malignant disease, other than that being treated in this study. Exceptions to this exclusion include the following: that were treated curatively and have not recurred within 5 years prior to study entry; completely resected basal cell and squamous cell skin cancers and completely resected carcinoma in situ of any type.
  6. Symptomatic which are neurologically unstable, or CNS metastases requiring local CNS directed therapy (such as radiotherapy or surgery), or increasing doses of within 2 weeks of first dose of study treatment.
  7. Serous effusion with symptoms (such as shortness of breath, abdominal distention, etc.).
  8. Major acute or chronic infections, including:

    1. Positive (HIV) antibody screening or known acquired immunodeficiency syndrome (AIDS);
    2. Active virus (HBV) or virus (HCV) infection: positive HBV-DNA copies (>2000 IU/mL) and/or other activity indicators; positive HCV antibody and HCV-RNA test result;
    3. active TB (such as exposure history or positive TB test; AND clinical symptoms, physical or imaging manifestations);
    4. Ongoing antibiotic treatment of serious acute infections.
  9. Previous treatment with a selective FGF19-FGFR4 targeted therapy and/or pan-FGFR inhibitor.
  10. Patients receiving treatment with cytochrome P450 (CYP)1A2, CYP2C9 and /5 substrates with a narrow therapeutic index (NTI) that cannot be discontinued for the duration of the study.
  11. Patients receiving known BSEP efflux transporter inhibitors that cannot be discontinued 3 days prior to the start of study treatment and during the course of the study.
  12. Current evidence of calcium-phosphate homeostasis impairment. See Section 5.3 for specific indicators.
  13. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral EVER4010001 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, small bowel resection).
  14. Ongoing active diarrhea requiring medications (e.g. bile acid sequestrant (BAS), loperamide).
  15. Irritable bowel syndrome with signs/symptoms or requires medications.
  16. Any previous specific target T cell co-stimulation or immune checkpoint pathway treatment, including but not limited to inhibitors, PD-L1 / 2 inhibitors or other targeted T cell drugs.
  17. Use of systemic chronic steroid therapy (≥ 10mg/day prednisone or equivalent) or any therapy two weeks prior to start of study treatment. Topical, inhaled, nasal and ophthalmic steroids are allowed.
  18. Use of any against infectious diseases within 4 weeks of initiation of study treatment (except inactivated seasonal influenza vaccines).
  19. Active known or suspected disease. Patients with vitiligo, residual hypothyroidism only requiring hormone replacement, or psoriasis not requiring systemic treatment can be included.
  20. History of severe reactions to any ingredient of study treatment and other monoclonal antibodies (mAbs) and/or their .
  21. Impaired cardiac function or clinically significant cardiac disease, including any of the following:

    -Clinically significant or uncontrolled heart disease such as congestive heart failure requiring treatment ( Grade ≥ 2), uncontrolled hypertension (defined by Systolic Blood Pressure > 160 mmHg/ Diastolic Blood Pressure > 100mmHg (average of three consecutive readings) at rest despite medical treatment, clinically significant arrhythmia; > 470 msec on screening or congenital long QT syndrome; acute myocardial infarction or unstable angina pectoris \< 3 months prior to screening.

  22. History of liver or other organ transplantation.
  23. History of interstitial lung disease or pneumonia requiring oral or intravenous steroids.
  24. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.
  25. Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of during dosing with study treatment and for the following duration after discontinuation of study treatment: See Section 5.3 for specific contraception methods.
  26. Sexually active males unless they use a condom during intercourse while receiving study treatment and for the following period after the last dose of study treatment, and should not father a child in this period.
  27. Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures. Any severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study treatment administration or that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for the study.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    EVER4010001 combination with Pembrolizumab

    EVER4010001 combination with Pembrolizumab, EVER4010001 started dose escalation from 40mg bid, and then to 60mg bid, 80mg bid, 100mg bid and 120 mg bid if applicable, dose escalation decision will be made by safety monitoring committee which is composed of the study team members. After phase II dose was recommended by safety monitoring committee, this dose will be applied to phase II patients. Pembrolizumab will be administered at 200mg every 3 weeks through the study.

    Drug: EVER4010001

Interventions

  • Please refer to information in arm/group descriptions.

    Also known as: Pembrolizumab

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicities (DLTs) observed in combined administration of EVER4010001 and Pembrolizumab

    Dose-limiting toxicities (DLTs) observed in combined administration of EVER4010001 and Pembrolizumab

    Time frame: up to 12 months

  2. Objective response rate (ORR) by IRC according to RECIST v 1.1

    Objective response rate (ORR) by IRC according to RECIST v 1.1

    Time frame: 3 years

Secondary outcomes

  1. PK parameters of EVER4010001: maximum observed concentration (Cmax)

    PK parameters of EVER4010001: maximum observed concentration (Cmax)

    Time frame: 3 years

  2. Objective response rate (ORR)

    Objective response rate (ORR)

    Time frame: 3 years

  3. Disease control rate (DCR)

    Disease control rate (DCR)

    Time frame: 3 years

  4. Duration of response (DOR)

    Duration of response (DOR)

    Time frame: 3 years

  5. Adverse events (AEs) and serious adverse events (SAEs) defined by National Cancer Institute-Common terminology criteria for adverse events (NCI-CTCAE) v5.0

    Adverse events (AEs) and serious adverse events (SAEs) defined by National Cancer Institute-Common terminology criteria for adverse events (NCI-CTCAE) v5.0

    Time frame: 3 years

  6. Exploratory biomarkers include Total bile acids, 7-α-hydroxy-4-cholesten-3-one (C4), circulating FGF19, etc.

    Exploratory biomarkers include Total bile acids, 7-α-hydroxy-4-cholesten-3-one (C4), circulating FGF19, etc.

    Time frame: 3 years

  7. Progression-free survival (PFS)

    Progression-free survival (PFS)

    Time frame: 3 years

  8. Overall survival (OS)

    Overall survival (OS)

    Time frame: 3 years

  9. Immunogenicity of Pembrolizumab: anti-drug antibody (ADA)

    Immunogenicity of Pembrolizumab: anti-drug antibody (ADA)

    Time frame: 3 years

  10. FGF19 expression in tumor cells and tumor microenvironment cells by immunohistochemical testing

    FGF19 expression in tumor cells and tumor microenvironment cells by immunohistochemical testing

    Time frame: 3 years

  11. PK parameters of EVER4010001: area under the concentration-time curve (AUC)

    PK parameters of EVER4010001: area under the concentration-time curve (AUC)

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
  • Department of Gastrointestinal Oncology, the Fifth Medical Center, Chinese PLA General Hospital
    Beijing, Beijing 100071, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2020 (actual). Primary completion is estimated for Jun 2023, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2020
First posted
Jan 7, 2021
StartActual
Jul 30, 2020
Primary completionEst.
Jun 2023
CompletionEst.
Jun 2023
Last update
Jan 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04699643
Lead sponsor
EverNov Medicines (Zhuhai Hengqin) Co., Ltd
Collaborators
Medidata Solutions
Responsible party
Sponsor
First posted
Jan 7, 2021
Start date
Jul 30, 2020
Primary completion
Jun 2023 (estimated)
Completion
Jun 2023 (estimated)
Last update
Jan 7, 2021

Study contacts

Mingxia Liu
Contact
mingxia.liu@everestmedicines.com
+86 10 65350128
Jianming Xu
principal investigator · Department of Gastrointestinal Oncology, the Fifth Medical Center, Chinese PLA General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion